BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 3.7% – Here’s Why

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s share price rose 3.7% during mid-day trading on Friday . The stock traded as high as $7.95 and last traded at $7.98. Approximately 1,042,637 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 2,741,884 shares. The stock had previously closed at $7.69.

Wall Street Analyst Weigh In

BCRX has been the subject of several research analyst reports. Needham & Company LLC upped their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Evercore ISI upped their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 target price for the company. Finally, JMP Securities restated a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Stock Performance

The firm’s 50-day moving average is $8.12 and its 200 day moving average is $7.82. The stock has a market cap of $1.67 billion, a PE ratio of -13.08 and a beta of 1.85.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. The business’s revenue was up 40.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.28 EPS. On average, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. California State Teachers Retirement System raised its position in BioCryst Pharmaceuticals by 4.1% during the 4th quarter. California State Teachers Retirement System now owns 184,485 shares of the biotechnology company’s stock worth $1,387,000 after buying an additional 7,232 shares during the last quarter. Mackenzie Financial Corp raised its position in BioCryst Pharmaceuticals by 190.7% during the 4th quarter. Mackenzie Financial Corp now owns 84,662 shares of the biotechnology company’s stock worth $637,000 after buying an additional 55,535 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in BioCryst Pharmaceuticals during the 4th quarter worth $33,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in BioCryst Pharmaceuticals by 3.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 401,111 shares of the biotechnology company’s stock worth $3,016,000 after buying an additional 11,581 shares during the last quarter. Finally, Woodline Partners LP purchased a new position in BioCryst Pharmaceuticals during the 4th quarter worth $3,385,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.